Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Stopped LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment of first line IO naïve patients. Safety data is consistent with the known safety profile of both drugs and no new safety issues have been observed
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- DRUG: Radium-223 dichloride (Xofigo, BAY 88-8223)
- DRUG: Pembrolizumab
Sponsor
Bayer
Collaborators